Keyora Antarctic Krill Oil EP-5: The EPA-DHA-DPA Architecture of Phospholipid Omega-3: Beyond EPA + DHA Metrics Toward Long-Chain n-3 Fatty Acid Identity, Metabolic Connectivity, and Evidence-Governed Interpretation

Background Omega-3 fatty acids represent one of the most extensively studied nutritional lipid categories, with EPA and DHA traditionally serving as the dominant quantitative markers for supplementation evaluation. The widespread use of the EPA + DHA metric has provided a practical method for comparing products and estimating long-chain omega-3 exposure. However, this simplified approach creates an important interpretive limitation. EPA and DHA represent only two members of a broader long-chain n-3 fatty acid family. Docosapentaenoic acid (DPA), although less frequently emphasized in consumer labeling and conventional supplementation discussions, represents an independent molecular entity within the same biological network. Therefore, a complete interpretation of Omega-3 composition requires more than measuring total EPA + DHA. It requires understanding: which fatty acids are present; their individual molecular identities; their relative proportions; their metabolic relationships; their structural context; and the evidence associated with each specific fatty-acid object. Keyora Antarctic Krill Oil EP-5 introduces the concept of the EPA-DHA-DPA Architecture of Phospholipid Omega-3 as a framework for interpreting marine Omega-3 composition beyond traditional EPA + DHA quantity-based evaluation. Objective This article develops Keyora [The EPA-DHA-DPA Architecture of Phospholipid Omega-3], a framework designed to reconstruct long-chain omega-3 composition according to molecular identity rather than aggregate numerical representation. The framework addresses five major questions: Why is EPA + DHA an incomplete representation of Omega-3 architecture? Why should EPA, DPA, and DHA be interpreted as separate molecular entities? How are these fatty acids connected through metabolic pathways while remaining non-interchangeable? Why does fatty-acid architecture provide additional information beyond total Omega-3 quantity? How should phospholipid Omega-3 preparations be evaluated according to composition, dose object, and evidence relevance? The objective is not to replace EPA + DHA measurement. EPA + DHA remains a valuable practical metric. The objective is to expand interpretation from a simplified quantity model toward a complete long-chain n-3 architecture model. The Limitation of EPA + DHA as a Complete Omega-3 Metric EPA + DHA has become the dominant shorthand for Omega-3 evaluation because these two fatty acids have substantial scientific recognition and extensive clinical research backgrounds. However, shorthand metrics inevitably compress biological information. A total EPA + DHA value provides information about two major fatty-acid components but does not reveal: whether DPA is present; the EPA:DHA:DPA distribution; the structural organization of the fatty-acid profile; the metabolic context; or the preparation architecture delivering these fatty acids. Therefore: EPA + DHA is useful. But EPA + DHA is not the complete Omega-3 identity. A complete interpretation requires restoration of individual fatty-acid visibility. EPA, DPA, and DHA as Distinct Molecular Objects EPA, DPA, and DHA belong to the same long-chain n-3 fatty-acid family. They share: carbon-chain characteristics; omega-3 classification; metabolic relationships. However, they remain chemically distinct molecules. EPA: 20 carbons; 5 double bonds. DPA: 22 carbons; 5 double bonds. DHA: 22 carbons; 6 double bonds. These structural differences influence: metabolic conversion; biological distribution; molecular interactions; and research interpretation. Therefore: metabolic connection does not mean molecular equivalence. The EPA-DPA-DHA Metabolic Continuum EPA, DPA, and DHA participate within connected metabolic pathways. The conventional biosynthetic pathway describes a relationship: ALA→ EPA→ DPA→ DHA However, this pathway should not be interpreted as a simple linear replacement system. Conversion efficiency varies according to: enzyme activity; tissue requirements; dietary exposure; metabolic conditions; age; physiological state. Therefore, dietary EPA, DPA, and DHA should be evaluated as individually delivered molecules rather than assumed substitutes for each other. The DPA Recognition Gate Keyora [The DPA Recognition Gate] addresses a major limitation in traditional Omega-3 interpretation. Because EPA and DHA dominate supplementation discussions, DPA is frequently absorbed into the broader “Omega-3 total” category. This creates a visibility problem. A fatty acid that is chemically distinct may disappear analytically when only EPA + DHA is considered. The purpose of DPA recognition is not to claim universal superiority. The purpose is: measurement accuracy; composition transparency; and complete molecular identification. DPA becomes important because it restores a missing component of the long-chain n-3 architecture. The EPA-DHA-DPA Architecture Model The EPA-DHA-DPA Architecture model changes the interpretation sequence. Traditional: Total Omega-3↓EPA + DHA amount Expanded: Total Omega-3↓EPA identity+DPA identity+DHA identity↓Relative architecture↓Metabolic interpretation↓Evidence matching This approach does not reject quantitative measurement. Instead, it adds molecular resolution. Phospholipid Omega-3 Context Within phospholipid Omega-3 systems, EPA, DHA, and DPA exist within a broader lipid architecture. The interpretation therefore requires two simultaneous questions: Fatty-acid question: How much EPA, DHA, and DPA are delivered? Structural question: Within what lipid environment are these fatty acids delivered? This distinction connects EP-5 with previous Keyora Antarctic Krill Oil frameworks. EP-2 established lipid form as a biological variable. EP-3 established phospholipid architecture as a structural membrane concept. EP-5 applies this framework specifically to fatty-acid composition. Dose Object Interpretation A major principle of EP-5 is: The measured number must be linked to the correct biological object. Examples: Total Omega-3: represents the aggregate long-chain omega-3 fatty-acid amount. EPA: represents EPA exposure. DHA: represents DHA exposure. DPA: represents DPA exposure. These objects cannot be freely substituted. A product containing higher total Omega-3 is not automatically equivalent to another product containing a different EPA-DHA-DPA distribution. Composition architecture matters. Evidence Interpretation Framework Human evidence should always be interpreted according to: exact fatty-acid composition; preparation; dose; duration; population; endpoint. Evidence generated from EPA+DHA supplementation cannot automatically establish identical conclusions for DPA-containing preparations. Likewise, DPA presence alone does not establish clinical superiority. Each fatty acid requires evidence matched to its molecular identity. Clinical and Nutritional Boundaries This framework does not claim: DPA is universally superior to EPA or DHA; EPA+DHA supplementation is incomplete or ineffective; DPA automatically produces specific clinical outcomes; phospholipid Omega-3 automatically outperforms all other Omega-3 forms. Instead, it establishes a more precise interpretation: Different Omega-3 molecules represent different biological objects. Complete evaluation requires recognizing the architecture of the fatty-acid profile. Conclusion Keyora Antarctic Krill Oil EP-5 establishes that Omega-3 interpretation should move beyond a simplified EPA + DHA quantity model toward an EPA-DHA-DPA architecture model. EPA, DPA, and DHA belong to the same long-chain n-3 family but remain distinct molecular entities. Their metabolic connectivity creates biological relationships. Their molecular differences create functional individuality. The scientific question is therefore no longer: “How much EPA + DHA does this product contain?” The more complete question becomes: “What long-chain n-3 fatty-acid architecture is delivered, in what preparation context, and how does that architecture correspond with the available evidence?” The EPA-DHA-DPA Architecture of Phospholipid Omega-3 provides a framework for interpreting marine Omega-3 composition with greater molecular precision, analytical transparency, and evidence alignment.